Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The statins as anticancer agents.

Kelvin K W Chan1, Amit M Oza, Lillian L Siu

  • 1Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, M5G 2M9 Canada.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|January 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting.

British journal of haematology·2026
Same author

A Prospective Population-Based Study of Chimeric Antigen Receptor T-Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma.

Current oncology (Toronto, Ont.)·2026
Same author

Refractory ultra-high-risk Choriocarcinoma achieving complete response to intensive multi-agent and intrathecal chemotherapy and anti-PD-L1 therapy.

Gynecologic oncology reports·2026
Same author

Breaking BRCA apart-how important is mutation location and shape in influencing outcome?

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

The association between cardiovascular medication use and survival in patients with advanced pancreatic adenocarcinoma.

Therapeutic advances in medical oncology·2026
Same author

Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial.

Nature communications·2026

Statins, or 3-hydroxy-3-methylglutaryl CoA reductase inhibitors, show promise as anticancer agents by disrupting cancer cell growth and metastasis. Ongoing trials are evaluating their efficacy and potential combination therapies for various cancers.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Statins (3-hydroxy-3-methylglutaryl CoA reductase inhibitors) are established cardiovascular drugs.
  • Emerging preclinical data suggest statins possess anticancer properties, including antiproliferative, proapoptotic, anti-invasive, and radiosensitizing effects.

Purpose of the Study:

  • To explore the potential of statins as anticancer agents.
  • To understand the mechanism of statin-induced anticancer effects via the mevalonate pathway.

Main Methods:

  • Review of preclinical evidence on statin antiproliferative, proapoptotic, anti-invasive, and radiosensitizing properties.
  • Analysis of statin's mechanism of action through inhibition of the mevalonate pathway.
  • Summary of findings from Phase I and ongoing Phase II clinical trials.

Related Experiment Videos

Main Results:

  • Statins inhibit 3-hydroxy-3-methylglutaryl CoA reductase, disrupting the mevalonate pathway and affecting critical cellular functions.
  • Preclinical studies demonstrate statins' growth inhibitory activity in cancer cell lines and animal models.
  • Phase I trials identified myotoxicity as the dose-limiting toxicity; Phase II trials are evaluating efficacy in various cancers.

Conclusions:

  • Statins demonstrate potential as anticancer agents by interfering with neoplastic cell processes.
  • Future research directions include combination therapies with chemotherapy, targeted agents, radiotherapy, and chemoprevention.